Neuphoria Therapeutics (NEUP) Total Non-Current Liabilities (2021 - 2026)
Neuphoria Therapeutics (NEUP) posted quarterly Total Non-Current Liabilities of $2.9 million for Q1 2026, down 37.87% year-over-year from $4.7 million in Q1 2025, and down 30.03% quarter-over-quarter from $4.2 million in Q4 2025.
Neuphoria Therapeutics (NEUP) Total Non-Current Liabilities (2021 - 2026) Analysis & Trends
Neuphoria Therapeutics (NEUP) has reported Total Non-Current Liabilities for 6 consecutive years, with $2.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Non-Current Liabilities fell 37.87% year-over-year to $2.9 million; the TTM figure through Mar 2026 stood at $2.9 million (down 37.87% YoY), while the FY2025 annual figure was $5.9 million, down 38.51% from the prior year.
- Total Non-Current Liabilities eased to $2.9 million in Q1 2026 per NEUP's latest filing, from $4.2 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $9.6 million in Q2 2024 and bottomed at $2.9 million in Q1 2026.
- Historically, Total Non-Current Liabilities has averaged $5.2 million across 5 years, with a median of $4.6 million in 2024.
- Annual changes were most pronounced in 2024 — Total Non-Current Liabilities surged 150.06% — and 2025, when it slumped 38.51%.
- Neuphoria Therapeutics' Total Non-Current Liabilities stood at $3.6 million in 2022, then gained by 5.99% to $3.8 million in 2023, then increased by 15.4% to $4.4 million in 2024, then fell by 5.26% to $4.2 million in 2025, then plunged by 30.03% to $2.9 million in 2026.
- Business Quant data shows NEUP's Total Non-Current Liabilities at $2.9 million in Q1 2026, $4.2 million in Q4 2025, and $6.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.20 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.17 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 9.32 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 724.15 Mn |
| 10 | Neuphoria Therapeutics | 21.37 Mn | 1.93 Mn | - | 2.93 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.93 Mn |
| Dec 31, 2025 | 4.18 Mn |
| Sep 30, 2025 | 6.74 Mn |
| Jun 30, 2025 | 5.89 Mn |
| Mar 31, 2025 | 4.71 Mn |
| Dec 31, 2024 | 4.42 Mn |
| Sep 30, 2024 | 5.84 Mn |
| Jun 30, 2024 | 9.57 Mn |
| Jun 30, 2023 | 3.83 Mn |
| Jun 30, 2022 | 3.61 Mn |
| Jun 30, 2021 | 3.32 Mn |